Photo from wikipedia
Key Points Question Is tumor mutational burden (TMB) associated with outcomes among patients with locally advanced unresectable non–small cell lung cancer (NSCLC) treated with definitive chemoradiation and consolidative durvalumab? Findings… Click to show full abstract
Key Points Question Is tumor mutational burden (TMB) associated with outcomes among patients with locally advanced unresectable non–small cell lung cancer (NSCLC) treated with definitive chemoradiation and consolidative durvalumab? Findings In this cohort study of 81 patients with locally advanced NSCLC treated with definitive chemoradiation and consolidative durvalumab, TMB-high status was associated with significantly improved 24-month locoregional failure and 24-month progression-free survival. Meaning These findings suggest that patients with unresectable locally advanced NSCLC with high TMB have a reduced risk of local-regional failure and improved progression-free survival after treatment with definitive chemoradiation and consolidative durvalumab.
Journal Title: JAMA Network Open
Year Published: 2023
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!